Healthcare Industry News: Ampion
News Release - March 4, 2009
Lilly's Anthony Murphy Announces RetirementSenior vice president of human resources to retire after more than 28 years of service
INDIANAPOLIS, March 4 (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY ) today announced that Anthony (Tony) Murphy, Ph.D., senior vice president of human resources, will be retiring from his position in April after nearly three decades in prominent HR roles at Lilly. The process to name Murphy's successor is underway and that person will be named at a later date.
Dr. Murphy first joined Lilly in 1980 as a personnel representative in Basingstoke, U.K., and was named to his current role in June 2005. During his 28-year career at Lilly, he held a variety of HR leadership positions in the United States and internationally, including executive director of HR for Europe, Japan, and the intercontinental region.
"Tony has played a key leadership role in driving the essential transformation of our company while keeping respect for people at the forefront of every discussion," said Lilly Chairman, President and CEO Dr. John Lechleiter. "He also has been a chAmpion of serving patients, helping employees across components and job levels draw a line of sight from their work to the people who depend on our medicines. I will miss his wisdom and friendship in our daily interactions, and I want to sincerely thank him for his loyalty and intense dedication to Lilly."
Born in Cardiff, Wales, United Kingdom, Murphy received a bachelor's degree from the University College Dublin in 1970 and a doctorate in psychology from the University of Wales in 1975. Prior to joining Lilly, Murphy lectured in industrial relations and worked as a consultant and researcher at the University of Bath, England. Murphy is a fellow of the Institute of Personnel and Development (U.K.) and a Chartered Psychologist.
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.
Source: Eli Lilly
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsLilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer
Thermo Fisher Scientific Signs Agreement with Lilly Oncology for Companion Diagnostic to be Used with RET Inhibitor
Lilly Receives U.S. FDA Approval for Taltz(R) (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)